LONDON, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that it today issued 251,125 new Ordinary Shares (the “New Ordinary Shares”) following the vesting of restricted stock units held by employees in the Company. Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM, with dealings expected to commence on 25 September 2018 (“Admission”). Following Admission, the Company will have a total of 105,326,638 Ordinary Shares in issue each carrying one voting right. The Company does not hold any Ordinary Shares in Treasury. This figure of 105,326,638 Ordinary Shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
Following the issue, Dr. Jan-Anders Karlsson, CEO of Verona Pharma, will have an interest in the Company of 193,545 Ordinary Shares, representing 0.18% of the Company’s issued share capital, and Mr. Piers Morgan, CFO of the Company, will have an interest in the Company of 58,594 Ordinary Shares, representing 0.06% of the Company’s issued share capital.
The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | Jan-Anders Karlsson |
| 2 | Reason for the notification | |
a) | Position/status | Director |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Verona Pharma plc |
| b) | LEI | 213800EVI6O6J3TIAL06 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 5 pence each GB00BYW2KH80 |
| b) | Nature of the transaction | Jan-Anders Karlsson was issued 101,145 Ordinary Shares following the vesting of restricted stock units under the Company’s employee share plan |
| c) | Price(s) and volume(s) | Price(s) Volume(s) N/A 101,145 Ordinary Shares |
| d) | Aggregated information - Aggregated volume - Price | N/A |
| e) | Date of the transaction | 20 September 2018 |
| f) | Place of the transaction | London Stock Exchange, AIM |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | Piers Morgan |
| 2 | Reason for the notification | |
a) | Position/status | Chief Financial Officer |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Verona Pharma plc |
| b) | LEI | 213800EVI6O6J3TIAL06 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 5 pence each GB00BYW2KH80 |
| b) | Nature of the transaction | Piers Morgan was issued 58,594 Ordinary Shares following the vesting of restricted stock units under the Company’s employee share plan |
| c) | Price(s) and volume(s) | Price(s) Volume(s) N/A 58,594 Ordinary Shares |
| d) | Aggregated information - Aggregated volume - Price | N/A |
| e) | Date of the transaction | 20 September 2018 |
| f) | Place of the transaction | London Stock Exchange, AIM |
For further information, please contact:
| Verona Pharma plc | Tel: +44 (0)20 3283 4200 |
| Jan-Anders Karlsson, Chief Executive Officer | info@veronapharma.com |
| Stifel Nicolaus Europe Limited (Nominated Adviser and UK Broker) | Tel: +44 (0) 20 7710 7600 |
| Stewart Wallace / Jonathan Senior / Ben Maddison |